Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
Daxor Corporation (Nasdaq: DXR) announced significant findings from a new pilot study published in the Journal of Critical Care, validating their Blood Volume Analysis (BVA) technology for COVID-19 and sepsis patients. The study revealed that 48% of COVID-19 patients were incorrectly assessed for fluid status by clinicians, highlighting the critical need for more accurate measurement tools.
The research demonstrated that sepsis patients showed higher albumin transudation rates compared to COVID-19 patients, indicating more severe blood vessel integrity breakdown. The study coincides with Daxor's recent FDA clearance in August 2025 for their new rapid BVA system, which is three times faster than their previous BVA-100™ analyzer while maintaining 95% accuracy.
Daxor Corporation (Nasdaq: DXR) ha pubblicato i risultati di un nuovo studio pilota sul Journal of Critical Care che validano la loro tecnologia di Blood Volume Analysis (BVA) per pazienti COVID-19 e con sepsi. Lo studio ha mostrato che il 48% dei pazienti COVID-19 era stato valutato in modo errato riguardo allo stato dei fluidi dai clinici, sottolineando l’importanza di strumenti di misurazione più precisi.
La ricerca ha inoltre evidenziato che i pazienti con sepsi presentano tassi più elevati di trasudazione di albumina rispetto ai pazienti COVID-19, segno di un danno più marcato all’integrità dei vasi sanguigni. Lo studio arriva in concomitanza con la recente approvazione FDA di agosto 2025 per il nuovo sistema BVA rapido di Daxor, che è tre volte più veloce rispetto al precedente analizzatore BVA-100™ mantenendo una accuratezza del 95%.
Daxor Corporation (Nasdaq: DXR) anunció hallazgos importantes de un nuevo estudio piloto publicado en el Journal of Critical Care que validan su tecnología de Blood Volume Analysis (BVA) para pacientes con COVID-19 y sepsis. El estudio reveló que el 48% de los pacientes con COVID-19 fue evaluado incorrectamente sobre su estado de fluidos por los clínicos, lo que pone de manifiesto la necesidad de herramientas de medición más precisas.
La investigación mostró además que los pacientes con sepsis presentaron tasas más altas de trasudación de albúmina en comparación con los pacientes COVID-19, lo que indica una mayor afectación de la integridad vascular. El estudio coincide con la reciente aprobación de la FDA en agosto de 2025 para su nuevo sistema BVA rápido, que es tres veces más rápido que su anterior analizador BVA-100™ y mantiene una precisión del 95%.
Daxor Corporation (Nasdaq: DXR)는 Journal of Critical Care에 게재된 새로운 파일럿 연구의 주요 결과를 발표하며 COVID-19 및 패혈증 환자에 대한 혈액량 분석(BVA) 기술을 검증했습니다. 연구는 임상의들이 COVID-19 환자의 48%를 체액 상태를 잘못 평가했음을 보여주어 보다 정확한 측정 도구의 필요성을 강조했습니다.
연구 결과 패혈증 환자는 COVID-19 환자보다 알부민 삼출률이 더 높아 혈관 완전성 손상이 더 심함을 시사했습니다. 이 연구는 Daxor가 최근 2025년 8월 FDA 승인을 받은 새로운 고속 BVA 시스템과 동시에 발표되었으며, 이 시스템은 기존 BVA-100™ 분석기보다 세 배 빠르면서 95%의 정확도를 유지합니다.
Daxor Corporation (Nasdaq: DXR) a annoncé des résultats significatifs d’une nouvelle étude pilote publiée dans le Journal of Critical Care, validant leur technologie Blood Volume Analysis (BVA) pour les patients COVID-19 et en sepsie. L’étude a révélé que 48 % des patients COVID-19 avaient été évalués de façon incorrecte par les cliniciens quant à leur statut hydrique, soulignant le besoin crucial d’outils de mesure plus précis.
La recherche a également montré que les patients en sepsie présentaient des taux de transsudation de l’albumine plus élevés que les patients COVID-19, indiquant une atteinte plus sévère de l’intégrité vasculaire. L’étude coïncide avec la récente validation par la FDA en août 2025 du nouveau système BVA rapide de Daxor, qui est trois fois plus rapide que leur ancien analyseur BVA-100™ tout en conservant une précision de 95 %.
Daxor Corporation (Nasdaq: DXR) veröffentlichte wichtige Ergebnisse einer neuen Pilotstudie im Journal of Critical Care, die ihre Blood Volume Analysis (BVA)-Technologie für COVID-19- und Sepsis-Patienten validiert. Die Studie zeigte, dass 48 % der COVID-19-Patienten von Klinikern falsch hinsichtlich ihres Flüssigkeitsstatus eingeschätzt wurden, was den dringenden Bedarf an genaueren Messinstrumenten hervorhebt.
Die Forschung ergab außerdem, dass Sepsis-Patienten höhere Albumintranssudationsraten aufwiesen als COVID-19-Patienten, was auf stärkere Schädigungen der Gefäßintegrität hinweist. Die Studie fällt mit der jüngsten FDA-Zulassung im August 2025 für Daxors neues schnelles BVA-System zusammen, das drei Mal schneller als das frühere BVA-100™-Analysegerät ist und dabei 95 % Genauigkeit beibehält.
- None.
- Clinical study reveals widespread misdiagnosis in current fluid assessment methods
- Study shows persistent capillary leakage issues in both COVID-19 and sepsis patients
Insights
Daxor's blood volume tech validated in critical COVID/sepsis study showing clinicians frequently misdiagnose patient fluid status, representing significant market opportunity.
The peer-reviewed study published in the Journal of Critical Care delivers compelling validation for Daxor's Blood Volume Analysis (BVA) technology in critical care settings. The research revealed a widespread clinical problem: approximately 48% of COVID-19 patients were incorrectly assessed as fluid overloaded when they were actually fluid deficient. Similarly, sepsis patients were frequently misclassified, highlighting a fundamental diagnostic gap in intensive care.
The study measured albumin transudation rate (ATR)—essentially how much fluid leaks from blood vessels into tissues—showing persistently elevated levels in both patient groups. Sepsis patients demonstrated significantly higher ATR than COVID-19 patients, indicating more severe vascular damage despite often having lower admission severity scores.
These findings represent a substantial clinical opportunity for Daxor's technology. Fluid management is a critical component of care in sepsis—a leading cause of hospital deaths—and accurate volume assessment can directly impact mortality rates. The newly FDA-cleared next-generation BVA system, which delivers results three times faster than their previous BVA-100™ while maintaining 95% accuracy, addresses the urgent need for rapid diagnostics in time-sensitive ICU environments.
The timing is particularly strategic with Daxor's August 2025 FDA clearance for their new rapid, battery-operated system that better aligns with ICU workflow requirements. The company appears well-positioned to capitalize on this validation, supported by non-dilutive funding from both the Department of Defense and National Institutes of Health—suggesting both military and civilian recognition of the technology's value proposition.
The market implications are significant as fluid management errors contribute to complications, extended hospital stays, and increased mortality. By providing objective measurements where subjective assessment frequently fails, Daxor's technology offers both clinical improvement and potential cost savings for healthcare systems struggling with sepsis management costs.
Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study
Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert Jan Bakker, M.D., Ph.D., this pivotal research reveals frequent inaccuracies in how doctors clinically assess fluid levels in critically ill patients with sepsis and COVID-19.
The research, titled, "Endothelial dysfunction in critically ill patients with sepsis and COVID-19 using the albumin transudation rate: A pilot study," found that patients were often misclassified during clinical assessment, with many mistakenly believed to be "hypervolemic" (fluid overloaded) when objective measurements showed them to be "hypovolemic" (fluid deficient), and vice-versa. This critical discrepancy can lead to insufficient fluid administration or dangerous fluid overload, highlighting a significant challenge in critical care.
Key Findings from the Study:
- Pervasive Misdiagnosis: Clinicians frequently misjudged the total blood volume (TBV) in patients suffering from COVID-19 or sepsis. For instance,
48% of COVID-19 patients were clinically deemed hypervolemic when objectively hypovolemic, and clinicians often misclassified sepsis patients as euvolemic or hypervolemic when they were hypovolemic - Persistent Capillary Leakage: The study showed that "albumin transudation rate (ATR)," a measure of fluid leaking from blood vessels into tissues, was persistently elevated in both sepsis and COVID-19 patients throughout their ICU stay
- Higher Leakage in Sepsis: Patients with sepsis exhibited significantly higher ATR than those with COVID-19, indicating a more severe and sustained breakdown in blood vessel integrity in sepsis, despite often having lower admission severity scores
- Urgent Need for Better Tools: The study concludes there is a "frequent inaccuracy in clinical fluid status assessment, which demands more reliable diagnostic tools to better guide fluid therapy in critically ill patients”
"This groundbreaking study reinforces what we at Daxor have long understood: accurate, real-time blood volume measurement is essential in critical care, especially for conditions that are characterized by fluid imbalances and widespread endothelial dysfunction," said Michael Feldschuh, Daxor’s President and CEO. "Sepsis, a leading cause of hospital deaths, benefits from effective individualized fluid management, and our BVA technology provides this unique capability to accurately measure volume where other existing methods sometimes fall short.”
Daxor’s FDA-approved BVA-100™ Analyzer was utilized in this study to objectively measure total blood volume and albumin transudation rates. The findings highlight the immense promise of Daxor's Blood Volume Analysis (BVA) technology in the Intensive Care Unit (ICU) and critical care settings. Mismanaged fluid levels can lead to severe complications, longer hospital stays, and increased mortality. By providing precise and direct measurements, BVA empowers care teams to make informed decisions, leading to better patient outcomes and significant cost savings for healthcare systems.
The need for rapid and accurate diagnostics in critical care is now more pressing than ever. This new research, coupled with Daxor’s recent FDA Clearance in August 2025 for its new rapid, lightweight, battery operated BVA system, positions Daxor to address this critical medical challenge. This next-generation analyzer, which is three times faster than the BVA-100™ but still over
Daxor leadership noted that "a meaningful expansion of the Company's revenue in the area of critical care medicine is possible, driven by a combination of new data, new funding opportunities, and our next-generation analyzer, which promises a speedy workflow critical to this specialty." The company continues to advance its technology with support from non-dilutive funding sources, including contracts from the U.S. Department of Defense and grants from the National Institutes of Health.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
brets@coreir.com|www.coreir.com
FAQ
What were the key findings of Daxor's (DXR) blood volume analysis study for COVID-19 patients?
How does Daxor's new BVA system compare to their previous BVA-100 analyzer?
What is the difference in albumin transudation rates between sepsis and COVID-19 patients according to Daxor's study?
When did Daxor (DXR) receive FDA clearance for their new rapid BVA system?
How is Daxor (DXR) funding their blood volume analysis technology development?
